NASDAQ:PLRX

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

Pliant Therapeutics logo
$0.69 0.00 (-0.55%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$0.69 0.00 (-0.03%)
As of 11/16/2026 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Pliant Therapeutics Stock (NASDAQ:PLRX)

Advanced

Key Stats

Today's Range
$0.66
▼
$0.71
50-Day Range
$0.69
▼
$1.17
52-Week Range
$0.66
▼
$1.72
Volume
999,035 shs
Average Volume
304,361 shs
Market Capitalization
$42.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Hold

Company Overview

Pliant Therapeutics is a biopharmaceutical company focused on developing medicines for fibrotic diseases, in which excess scar tissue can impair the function of organs. The company’s research centers on integrins, proteins involved in processes such as tissue repair and fibrosis.

Its investigational programs have included bexotegrast, an oral drug designed to inhibit the αvβ6 and αvβ1 integrins and studied for conditions including idiopathic pulmonary fibrosis. Pliant has also pursued other drug candidates targeting fibrotic disease pathways. These medicines are investigational and are not approved treatments.

Based in South San Francisco, California, Pliant has conducted clinical research in the United States and other countries. Its work is focused on drug discovery and development rather than providing medical products or services directly to patients.

AI Generated. May Contain Errors.

Pliant Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

PLRX MarketRank™: 
1.466480446925 of 5 stars

Pliant Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 776th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pliant Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Pliant Therapeutics has a consensus price target of $3.00, representing about 332.8% upside from its current price of $0.69.

  • Amount of Analyst Coverage

    Pliant Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Pliant Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($1.42) to ($1.53) per share.

  • Price to Book Value per Share Ratio

    Pliant Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.64% of the float of Pliant Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pliant Therapeutics has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pliant Therapeutics has recently increased by 5.32%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pliant Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pliant Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Pliant Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Pliant Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    8.74% of the stock of Pliant Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pliant Therapeutics' insider trading history.
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PLRX Stock News Headlines

Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
See More Headlines

PLRX Stock Analysis - Frequently Asked Questions

Pliant Therapeutics' stock was trading at $1.22 on January 1st, 2026. Since then, PLRX stock has decreased by 43.2% and is now trading at $0.6932.

Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted its earnings results on Thursday, November, 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02.

Pliant Therapeutics (PLRX) raised $135 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 9,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

Top institutional investors of Pliant Therapeutics include State Street Corp (0.41%) and Empowered Funds LLC (0.13%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull, Mike Ouimette and Minnie Kuo.
View institutional ownership trends
.

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include Cabaletta Bio (CABA), NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Black Diamond Therapeutics (BDTX), ADC Therapeutics (ADCT) and Gossamer Bio (GOSS).

Company Calendar

Last Earnings
11/12/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PLRX
CIK
1746473
Fax
N/A
Employees
49
Year Founded
2016

Price Target and Rating

High Price Target
$3.00
Low Price Target
$3.00
Potential Upside/Downside
+332.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$149.34 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-53.84%
Return on Assets
-43.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.90
Quick Ratio
9.90

Sales & Book Value

Annual Sales
$1.58 million
Price / Sales
27.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.95 per share
Price / Book
0.23

Miscellaneous

Outstanding Shares
61,920,000
Free Float
56,510,000
Market Cap
$42.92 million
Optionable
Optionable
Beta
1.36

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PLRX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners